Bone Biologics Corporatio... (BBLG)
Bone Biologics Corporation (BBLG) Stock Price, Analysis & Data
| Bid | 0.5 |
| Market Cap | 1.19M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -2.86M |
| Beta | 0.53 |
| EPS (ttm) | -1.16 |
| PE Ratio (ttm) | n/a |
| Forward PE | -1.03 |
| P/B (ttm) | 0.25 |
| P/S (ttm) | n/a |
| Earnings Date | n/a |
| Ask | 0.82 |
| Volume | 14,669,682 |
| Avg. Volume (20D) | 65,996 |
| Open | 0.69 |
| Previous Close | 0.91 |
| Day's Range | 0.62 - 0.73 |
| 52-Week Range | 0.62 - 4.13 |
| Analyst | n/a |
| Price Target | 12.2 (1748.48%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About BBLG
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration. The company also develops NB1, a NELL-1/DBM fusion device for use in lumbar spinal fusion, as well as spine implants, non-union trauma cases, a...
Financial Performance
In 2025, Bone Biologics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -3.11M, a decrease of -24.4%.
Financial StatementsAnalyst Forecast
According to 1 analyst ratings, the average rating for BBLG stock is "null". The 12-month stock price forecast is 12.2, which is upside of 1748.48% from the latest price.
Stock ForecastsEarnings Surprise
11 months ago · Associated Press Finance
BC-Most Active Stockstd class="col-issue">Next Technology Holding Inc.